144 related articles for article (PubMed ID: 10688166)
1. Congress gets tough with gene therapy.
Smaglik P
Nature; 2000 Feb; 403(6770):583-4. PubMed ID: 10688166
[No Abstract] [Full Text] [Related]
2. NIH tightens up monitoring of gene-therapy mishaps.
Smaglik P
Nature; 2000 Mar; 404(6773):5. PubMed ID: 10716412
[No Abstract] [Full Text] [Related]
3. Gene therapy investigations proliferate.
Hollon T
Nat Med; 2000 Mar; 6(3):235. PubMed ID: 10700200
[No Abstract] [Full Text] [Related]
4. Light, fast, and flexible: a new approach to regulation of human gene therapy.
Cregan JA
McGeorge Law Rev; 2000; 32(1):261-87. PubMed ID: 15709266
[No Abstract] [Full Text] [Related]
5. More flexibility on reporting to federal agencies about injuries to research subjects.
Maloney DM
Hum Res Rep; 2002 Jan; 17(1):1-2. PubMed ID: 16270435
[No Abstract] [Full Text] [Related]
6. NIH under fire over gene-therapy trials..
Wadman M
Nature; 2000 Jan; 403(6767):237. PubMed ID: 10659820
[No Abstract] [Full Text] [Related]
7. Making clinical trials safer for human subjects.
Baram M
Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112
[No Abstract] [Full Text] [Related]
8. Proposed requirements for informed consent go beyond current federal regulations.
Hum Res Rep; 1994 Jul; 9(7):1-3. PubMed ID: 11659879
[No Abstract] [Full Text] [Related]
9. FDA halts all gene therapy trials at Penn.
Marshall E
Science; 2000 Jan; 287(5453):565, 567. PubMed ID: 10691531
[No Abstract] [Full Text] [Related]
10. Tighter watch urged on adenoviral vectors...with proposal to report all 'adverse events'.
Smaglik P
Nature; 1999 Dec; 402(6763):707. PubMed ID: 10617181
[No Abstract] [Full Text] [Related]
11. Informed consent: the FDA's perspective.
Bagley G
Food Drug Law J; 1993; 48(2):181-6. PubMed ID: 11653141
[No Abstract] [Full Text] [Related]
12. Gene therapy institute denies that errors led to trial death.
Smaglik P
Nature; 2000 Feb; 403(6772):820. PubMed ID: 10733385
[No Abstract] [Full Text] [Related]
13. A gene therapy death.
Silberner J
Hastings Cent Rep; 2000; 30(2):6. PubMed ID: 10763464
[No Abstract] [Full Text] [Related]
14. RNA interference: a critical analysis of the regulatory and ethical issues encountered in the development of a novel therapy.
McKnight R
Albany Law J Sci Technol; 2004; 15(1):73-108. PubMed ID: 17340758
[No Abstract] [Full Text] [Related]
15. Restoring public trust in gene therapy.
Kennedy EM
J Biolaw Bus; 2001; 4(3):3-4. PubMed ID: 12962103
[No Abstract] [Full Text] [Related]
16. Back from the brink.
Nature; 2001 Jul; 412(6845):361. PubMed ID: 11473267
[No Abstract] [Full Text] [Related]
17. Agencies look to improve informed consent.
Science; 1996 Aug; 273(5275):567. PubMed ID: 11644820
[No Abstract] [Full Text] [Related]
18. Continued concern: human subject protection, the institutional review board, and continuing review.
Hoffman S
Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
[No Abstract] [Full Text] [Related]
19. Parents say federal agency helps protect researchers from more than their subjects.
Maloney DM
Hum Res Rep; 2000 Oct; 15(10):5-6. PubMed ID: 11913435
[No Abstract] [Full Text] [Related]
20. Questions and answers.
Goodwin FK
J Calif Alliance Ment Ill; 1994; 5(1):45-7. PubMed ID: 11653321
[No Abstract] [Full Text] [Related]
[Next] [New Search]
